"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a

av J Widjestam · 2012 — 2012 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis

I Maxim finns i dag huvudsakligen två projekt, dels substansen Ceplene mot en form av blodcancer, akut myeloisk leukemi (AML), dels substanser mot apoptos Pivotal Trial of its AML Therapy Ceplene® in Combination with Low Dose IL-2 the maintenance of remission in patients with Acute Myeloid Leukemia (AML). Ceplene är den första effektiva läkemedlet som bromsar och även stopparåterfsll i AML (Acutr Myloid Leukemi). Nu gälleer det "allt eller inget" i Akut myeloisk leukemi (AML) AML. ALL. AL ospec. Onk.ssk-kurs_jan.2013. De novo AML. (80%). Sekundär AML (20%) histamin (Ceplene®) + interleukin-2. (FDA) kräver ytterligare en fas III-studie av Maxims cancermedel Ceplene för behandling av akut myeloisk leukemi (AML).

The study was conducted in eleven countries. The results showed that patients with AML in complete remission who received 18 months of treatment with Ceplene (histamine dihydrochloride) plus low dose interleukin-2 (IL-2) experienced a significantly improved leukemia-free survival compared to the current standard of care. 2018-11-27 histamine dihydrochloride, 500 microgram/0.5ml, vial (Ceplene options for patients with AML who are in CR1 following induction or consolidation regimens. Clinically relevant loss of quality of life was not seen in the treatment group versus the standard care group. Following a meeting with the US FDA, EpiCept has confirmed it will have to include an interleukin-2 (IL-2) monotherapy arm in its additional Phase III trial investigating its lead drug candidate, Ceplene (histamine dihydrochloride), in combination with a low-dose IL-2 for the remission maintenance and prevention of relapse of patients with acute myeloid leukaemia (AML) in first complete Meda of Sweden has licensed exclusive rights to Ceplene (histamine dihydrochloride) from US firm EpiCept. Meda licenses EpiCept's Ceplene for AML in Europe :: Scrip We use cookies to improve your website experience.

Ceplene(histamine dihydrochloride) An overview of Ceplene and why it is authorised in the EU . What is Ceplene and what is it used for? Ceplene is a medicine used in combination with interleukin -2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affe cting the white blood cells.

AML är sällsynt och Ceplene "Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a Underhållsbehandling med IL-2-histamin (Proleukin + Ceplene) kan övervägas för patienter som har AML M4/M5 i CR1 och som inte är lämpliga för allo-SCT. Indikationen för Ceplene är underhållsbehandling och förebyggande av återfall hos vuxna med akut myeloid leukemi (AML).

Akut myeloisk leukemi (AML) AML. ALL. AL ospec. Onk.ssk-kurs_jan.2013. De novo AML. (80%). Sekundär AML (20%) histamin (Ceplene®) + interleukin-2.

Används endast på sjukhuset. dos. Finns som en spruta under huden. Ceplene is with the Swedish guidelines for the treatment of AML, and Ceplene was observed in two different reports from approved drugs in the EU in 2008. I en multicenterstudie förlängde Ceplene den leukemifria överlevnaden för AML patienter i första remission , det primära målet med studien. Skillnaden mellan den behandlade gruppen och kontrollgruppen var i hög grad statistiskt signifikant (p<0.008). Ceplene har godkänts av EU-kommissionen som en orphan drug .

Research Study.
Sheffield trams

Ceplene has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival while maintaining good quality of life during treatment. Ceplene(histamine dihydrochloride) An overview of Ceplene and why it is authorised in the EU . What is Ceplene and what is it used for? Ceplene is a medicine used in combination with interleukin -2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affe cting the white blood cells. Ceplene (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2) for maintenance of remission in patients with AML following successful induction therapy.

Ceplene is a medicine used in combination with interleukin -2 (a cancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affe cting the white blood cells. Ceplene (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2) for maintenance of remission in patients with AML following successful induction therapy. En senare subgruppsanalys har visat att andelen som svarade på behandlingen var markant högre bland AML-patienter med FAB-typ M4/M5 (Thoren et al., 2009).
Bim objects sverige

Ceplene (histamine dihydrochloride) is an immunostimulant that is administered in conjunction with low-dose interleukin-2 for maintenance of first remission in patients with AML. Ceplene has been shown in an international phase III clinical study to prevent relapse of leukemia in AML patients in first remission while maintaining good quality of life during treatment.

Article Mylan sells Ceplene rights back to owner. 15-06-2017. Article Immune Pharma restructuring sees likely spin-out.

Zoonos djur

The active substance in Ceplene, histamine dihydrochloride, is an immune modulator. In the treatment of AML, it is thought to work by protecting immune system

Aktiva ämnen . histaminhydroklorid.